Chinese scientist probed after girl, 6, dies post gene-editing trial
Synopsis
A six-year-old girl identified as Mei died seven days after receiving an experimental base-editing gene therapy led by Shanghai Jiao Tong University neuroscientist Qiu Zilong. The hospital was fined just US$3,500. Now the university has launched a formal probe — echoing the He Jiankui scandal.
Key Takeaways
Qiu Zilong , a neuroscientist at Shanghai Jiao Tong University , is under institutional investigation following the death of a six-year-old girl after an experimental gene-editing therapy.
The child, Mei , died in March 2025 — seven days after trillions of viruses carrying a base-editing recipe were infused into her spinal fluid.
Her parents attributed her death to a fatal immune reaction linked directly to the experimental treatment.
Xinhua Hospital , affiliated with Shanghai Jiao Tong University , paid a fine of approximately 24,000 yuan (US$3,500) to local health authorities in September 2025 .
The case was exposed through a joint investigation by Science and Retraction Watch , drawing global comparisons to the He Jiankui gene-edited babies scandal.
Qiu Zilong, a neuroscientist at Shanghai Jiao Tong University's brain centre, is under formal investigation by his institution after a six-year-old girl reportedly died following an experimental base-editing gene therapy he led in March 2025. The case, surfaced through a joint investigation by Science and Retraction Watch, has reignited global scrutiny over the oversight of experimental gene therapies on paediatric patients in China.
What happened
The child, identified only as Mei, received a treatment designed to correct a genetic mutation affecting her neurodevelopment. Seven days after her medical team infused trillions of viruses carrying the recipe for the base editor into her spinal fluid, she died of a severe immune reaction linked to the therapy, according to Science and Retraction Watch. Her parents said the fatal immune reaction was directly linked to the experimental treatment.
The trial and its oversight
Qiu Zilong has been researching ways to adapt base editing — a precise form of gene editing that chemically alters individual DNA letters — into treatments for children with rare diseases. Xinhua Hospital, affiliated with Shanghai Jiao Tong University, paid a fine of approximately 24,000 yuan (US$3,500) to local health authorities in September 2025 following the incident. At the time, Qiu faced no public sanctions.
Why it matters
The case draws uncomfortable parallels with that of He Jiankui, the Chinese scientist who was imprisoned in 2019 after creating the world's first gene-edited babies, exposing deep gaps in clinical trial governance for cutting-edge genetic interventions. Base editing is considered a next-generation advance over earlier CRISPR techniques, and its application in paediatric rare-disease trials is expanding rapidly worldwide. A child's death from immune toxicity raises urgent questions about informed consent, pre-clinical safety thresholds, and the adequacy of institutional review boards overseeing such trials.
The competitive backdrop
China has aggressively positioned itself as a global leader in gene-editing research, with significant state investment flowing into programmes targeting rare neurological conditions in children. The relative speed of clinical translation — moving from laboratory findings to human trials — has frequently outpaced the regulatory frameworks designed to protect vulnerable participants. The modest fine levied on Xinhua Hospital has drawn criticism as disproportionate to the gravity of the outcome.
What's next
Shanghai Jiao Tong University's ongoing investigation into Qiu Zilong will be closely watched by the international scientific community and regulators. The findings of Science and Retraction Watch are likely to prompt calls for stricter pre-clinical safety requirements and independent ethics oversight for gene-editing trials involving minors in China and beyond. Whether Chinese health authorities escalate sanctions beyond the hospital-level fine will signal how seriously the country's regulatory apparatus treats experimental therapy deaths.
Point of View
500 hospital fine for a child's death in an unauthorised or inadequately supervised experimental trial is not a deterrent — it is an incentive to under-report. What mainstream coverage underweights is the systemic pressure on Chinese academic institutions to publish and translate rapidly, creating conditions where informed consent and pre-clinical toxicity thresholds can be compressed. Until independent, internationally benchmarked ethics review becomes mandatory for paediatric gene-therapy trials in China, the He Jiankui episode will not remain an outlier.
NationPress
26 Jul 2026
Frequently Asked Questions
Who is Qiu Zilong and what is he being investigated for?
Qiu Zilong is a neuroscientist at Shanghai Jiao Tong University's brain centre who led an experimental base-editing gene therapy trial. He is under investigation by his university after a six-year-old girl died seven days after receiving the therapy in March 2025 , reportedly from a severe immune reaction.
What is base editing and why was it used on a child?
Base editing is a precise form of gene editing that chemically alters individual DNA 'letters' without cutting the double helix, considered a next-generation advance over CRISPR. Qiu Zilong was researching its application as a treatment for children with rare genetic diseases affecting neurodevelopment, and Mei received it to correct a specific genetic mutation.
What punishment did the hospital and scientist face?
Xinhua Hospital , affiliated with Shanghai Jiao Tong University , paid a fine of approximately 24,000 yuan (US$3,500) to local health authorities in September 2025 . At that time, Qiu Zilong faced no public sanctions; the university investigation was launched only after the case was reported by Science and Retraction Watch .
How does this compare to the He Jiankui gene-edited babies case?
The case echoes the scandal involving He Jiankui , who was imprisoned in 2019 after creating the world's first gene-edited babies without adequate ethical oversight. Both cases highlight the risk of experimental genetic interventions on humans outpacing China's regulatory and ethics review frameworks.
What happens next in the investigation?
Shanghai Jiao Tong University's formal investigation into Qiu Zilong is ongoing. The international scientific community and regulators are watching whether Chinese health authorities escalate penalties beyond the hospital-level fine, and whether the case will trigger stricter national requirements for ethics oversight in paediatric gene-therapy trials.
